Author/Authors :
lu, hao nanjing medical university - liver transplantation center, first affiliated hospital, Nanjing, China , lu, ling nanjing medical university - liver transplantation center, first affiliated hospital, Nanjing, China , zhang, feng nanjing medical university - liver transplantation center, first affiliated hospital, Nanjing, China , zhai, yuan nanjing medical university - liver transplantation center, first affiliated hospital, Nanjing, China , wang, xuehao nanjing medical university - liver transplantation center, first affiliated hospital, Nanjing, China
Abstract :
Liver transplantation (LT) remains a lifesaving therapy for patients with end-stage liver disease, but the shortage of graft donor (deceased donor) limits development of LT. Living donor liver transplantation (LDLT) is the only alternative to deceased donor liver transplantation (DDLT), but LDLT requires more sophisticated surgical techniques. In addition, LDLT does not have the advantage in their survival in response to immunosuppressive therapies. In this paper, we reviewed recent development of LDLT in China mainland, especially surgical technique and immune therapy.
Keywords :
Living donor liver transplantation (LDLT) , small , for , size syndrome (SFSS) , immune therapy , regulatory T cells (Tregs)
